See more : Gaush Meditech Ltd (2407.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Keen Vision Acquisition Corporation Ordinary Shares (KVAC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Keen Vision Acquisition Corporation Ordinary Shares, a leading company in the Shell Companies industry within the Financial Services sector.
- Wuchan Zhongda Group Co.,Ltd. (600704.SS) Income Statement Analysis – Financial Results
- Adtec Plasma Technology Co., Ltd. (6668.T) Income Statement Analysis – Financial Results
- illimity Bank S.p.A. (ILTY.MI) Income Statement Analysis – Financial Results
- Shoei Co., Limited (SHOFF) Income Statement Analysis – Financial Results
- Phillips Edison & Company, Inc. (PECO) Income Statement Analysis – Financial Results
Keen Vision Acquisition Corporation Ordinary Shares (KVAC)
About Keen Vision Acquisition Corporation Ordinary Shares
Keen Vision Acquisition Corporation intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, and related business combination with one or more businesses or entities. It intends to focus on businesses in the biotechnology, consumer goods, and agriculture sectors. The company was incorporated in 2021 and is based in Summit, New Jersey.
| Metric | 2023 | 2022 | 2021 |
|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 478.68K | 0.00 | 0.00 |
| Gross Profit | -478.68K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% |
| Research & Development | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 |
| SG&A | 4.00 | 697.00 | 3.07K |
| Other Expenses | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 4.00 | 697.00 | 3.07K |
| Cost & Expenses | 478.68K | 697.00 | 3.07K |
| Interest Income | 1.93M | 4.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 167.90K | 228.49K | 236.56K |
| EBITDA | 0.00 | -697.00 | -3.07K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% |
| Operating Income | -478.68K | -697.00 | -3.07K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.93M | 4.00 | -3.00 |
| Income Before Tax | 1.45M | -693.00 | -3.07K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -228.49K | -236.56K |
| Net Income | 1.45M | -693.00 | -3.07K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% |
| EPS | 0.08 | 0.00 | 0.00 |
| EPS Diluted | 0.08 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 19.37M | 16.87M | 19.37M |
| Weighted Avg Shares Out (Dil) | 19.37M | 16.87M | 19.37M |
Medera Announces Publication of Study Utilizing Machine Learning to Enhance Next-Generation Drug Screening with Human mini-Heart Technology
Medera Announces Completion of Cohort A and Initiation of Dosing in Cohort B of MUSIC-HFpEF, a Phase 1/2a Clinical Trial Evaluating First-In-Human Gene Therapy SRD-002 for Heart Failure with Preserved Ejection Fraction
STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Merger of Keen Vision Acquisition Corp. - KVAC
Medera Inc. to be Listed on NASDAQ Through a Merger Agreement with Keen Vision Acquisition Corporation
Keen Vision Acquisition Corporation Announces the Separate Trading of its Ordinary Shares and Warrants, Commencing September 15, 2023
Source: https://incomestatements.info
Category: Stock Reports